Latest Roger Lo Stories

A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true. The study by researchers at UCLA's Jonsson Comprehensive Cancer Center found that patients with the mutations in both the MEK1 and BRAF genes respond as well to the inhibitors as patients with the BRAF mutation alone. Another surprising finding is that the MEK1 and BRAF...

(Ivanhoe Newswire) – Cancer has various ways of evading drugs used by oncologists to try and eliminate the disease. Now, new research is showing how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene. Scientists examined the part of the melanoma genome that encodes proteins (called the exome) and discovered that in some patients with BRAF-mutated metastatic melanoma, the mutated BRAF gene that forms the cancer becomes amplified as the...

Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene. By examining the part of the melanoma genome that encodes proteins, called the exome, Jonsson Cancer Center scientists discovered that in some patients with BRAF-mutated metastatic melanoma, the...

About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.In a study published today as a Priority Report in the peer-reviewed journal Cancer Research, scientists at UCLA's Jonsson Comprehensive Cancer Center tested a combination of...